LC
CCCC icon

Lindbrook Capital’s C4 Therapeutics CCCC Stock Holding History

Lindbrook Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$570 – 2798
2024
Q3 		$570 Buy
+100
New +$602 ﹤0.01% 2632
2023
Q1 		– Sell
-31
Closed -$183 – 2796
2022
Q4 		$183 Sell
31
-304
-91% -$2.52K ﹤0.01% 2734
2022
Q3 		$3K Buy
335
+304
+981% +$3.16K ﹤0.01% 1848
2022
Q2 		$0 Sell
31
-52
-63% -$458 ﹤0.01% 2511
2022
Q1 		$2K Buy
+83
New +$2.02K ﹤0.01% 1955

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lindbrook Capital's CCCC Position: Q4 2024 in Review

Lindbrook Capital sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 100 shares — an estimated $570 sold.

Lindbrook Capital first reported a position in CCCC in Q1 2022 and held it in 5 quarters. The position peaked at $3K in Q3 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Lindbrook Capital reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 100 C4 Therapeutics shares in Q4 2024, an estimated $570.
  • Lindbrook Capital first reported a position in C4 Therapeutics in Q1 2022 and held it in 5 quarters.
  • Lindbrook Capital's C4 Therapeutics position peaked at $3K in Q3 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.